Skip to main content
Premium Trial:

Request an Annual Quote

TriLink, Biofortuna Ink New Licensing Deal for CleanAmp

NEW YORK (GenomeWeb News) – Trilink BioTechnologies said today that it has inked a new licensing agreement with Biofortuna allowing the UK firm to use Trilink's hot start deoxynucleotides for freeze-drying molecular diagnostic kit development and production service.

Biofortuna offers this product to "diagnostic companies looking to develop stabilized molecular diagnostic kits," said Mike Bunce, chief science officer of Biofortuna, in a statement.

This agreement is an extension of one signed in 2010 that permitted Biofortuna to use these deoxynucleotides in their own molecular diagnostics kits. The lyophilized kits, called SSPGo, are distributed exclusively by Abbott Molecular and contain buffers, primers, as well as Taq polymerase, and are stable for more than a year at temperatures up to 37°C.

Incorporation of TriLink's CleanAmp dNTPS allows the freeze dried kits to be hot start, meaning DNA polymerase remains inactive below a threshold temperature, which enhances detection of low concentrations of template DNA.

The companies will co-host a corporate workshop on freeze dried hot start PCR mixes at the Association of Molecular Pathology annual meeting being held next week in Phoenix Ariz.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.